Resecurity Joins U.S.-U.A.E. Business Council to Strengthen Cybersecurity Collaboration in the Middle East

LOS ANGELES--(BUSINESS WIRE)--Resecurity®, a leading U.S.-based cybersecurity company, proudly announces its official membership in the U.S.-U.A.E. Business Council, a premier organization dedicated to advancing commercial ties between the United States and the United Arab Emirates.
The U.S.-U.A.E. Business Council plays a pivotal role in enhancing the bilateral relationship between the United States and the U.A.E. through high-level engagement with business and government leaders. It provides its members with unique access to exclusive networking opportunities, market intelligence, and strategic insights that foster mutual investment and innovation across sectors including energy, healthcare, defense, technology, and cybersecurity.
'We are delighted to welcome Resecurity to the U.S.-U.A.E. Business Council,' said Danny Sebright, President of the U.S.-U.A.E. Business Council. 'Resecurity brings deep expertise in cybersecurity and threat intelligence, and their participation will add tremendous value to our growing technology and cybersecurity-focused initiatives. We look forward to supporting their efforts to build strong partnerships and enhance digital resilience in the U.A.E. and across the region.'
'Our membership in the U.S.-U.A.E. Business Council reflects our long-term commitment to building trusted relationships in the Middle East,' said Gene Yoo, CEO of Resecurity. 'As the U.A.E. continues to lead regional digital transformation, we are excited to contribute our expertise in threat intelligence and cybersecurity innovation to support its vision for a secure and resilient digital future.'
Resecurity has been actively expanding its footprint in the Middle East and GCC regions, working with governments and enterprises to tackle emerging cyber threats, enhance digital resilience, and secure critical infrastructure. This collaboration with the U.S.-U.A.E. Business Council will further support efforts to bridge the cybersecurity gap and enable knowledge-sharing between international partners.
About Resecurity
Resecurity® is a cybersecurity company that delivers a unified endpoint protection, risk management, and cyber threat intelligence platform. Known for providing best-of-breed data-driven intelligence solutions, Resecurity services and platforms focus on early-warning identification of data breaches and comprehensive protection against cybersecurity risks. Founded in 2016, it has been globally recognized as one of the world's most innovative cybersecurity companies with the sole mission of enabling organizations to combat cyber threats regardless of how sophisticated they are. Most recently, Resecurity was named one of the Top 10 fastest-growing private cybersecurity companies in Los Angeles, California, by Inc. Magazine. An Official Partner of the Cybercrime Atlas by the World Economic Forum (WEF), Member of InfraGard National Members Alliance (INMA), AFCEA, NDIA, SIA, FS-ISAC and the American Chamber of Commerce in Saudi Arabia (AmChamKSA), Singapore (AmChamSG), Korea (AmChamKorea), Mexico (AmChamMX), Thailand (AmChamThailand), and UAE (AmChamDubai). To learn more about Resecurity, visit https://resecurity.com.
The U.S.-U.A.E. Business Council is the premier business organization dedicated to advancing bilateral commercial relations between the United States and the United Arab Emirates. Through its programs, events, and policy work, the U.S.-U.A.E. Business Council provides its members with unparalleled access to senior decision-makers in both countries and facilitates strategic partnerships across various sectors. To learn more about the U.S.-U.A.E. Business Council, visit https://usuaebusiness.org.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

6 hours ago

• Business Wire

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.

Travel Weekly

6 hours ago

• Travel Weekly

Hawaii visitor satisfaction remains high, but Canadians might stay away

Christine Hitt A new study finds that while Hawaii visitor satisfaction remains high, recent Canadian visitors are less likely to return, due in part to the political climate. The Hawaii Department of Business, Economic Development & Tourism released its visitor satisfaction study for the first quarter of 2025. The results come from a survey of recent visitors from eight markets, including U.S. West, U.S. East, Japan, Canada and Europe. Hawaii received satisfactory marks, with most visitors in all markets rating it a 7 out of 8. Trip expectations also saw positive movement, with increases of "exceeded expectations" selections seen in the markets of U.S. West, U.S. East, Canada, Oceania, Korea, China and Europe. The report found that repeat visitors from U.S. West gave higher satisfactory scores compared to first-time visitors from the same market. Also, travel party size among visitors from U.S. East made a difference: Travelers in groups of three or more people gave higher scores than those traveling alone. Repeat visitors from U.S. West, U.S. East, Oceania and Japan were more likely to return to the state than first-time visitors. The study also found that traveler with higher incomes and education in U.S. West markets were more likely to return. Canadian visitors less likely to return When visitors were asked whether they are likely to return to Hawaii in the next five years, the number of Canadian visitors had the largest differential. Only 55% of Canadians said that they were "very likely" to return, compared to 68% in the first quarter of 2024. Compared to the last 10 years, 2025 ranks the lowest. Last year, Canadians' top reason for not returning was that it is "too expensive" (60%). This year, Canadians' responses include political climate (45%), high cost of travel (30%), long-distance travel (12%) and travel restrictions or relations (12%). "High cost of travel" remains a top reason for not returning for U.S. West (48%), U.S. East (42%), Japan (34%), Oceania (48%), Korea (57%) and Europe (40%) markets.

Chicago Tribune

a day ago

• Chicago Tribune

Former EPA administrator, activists react to 'One Big Beautiful Bill'

As President Donald Trump touts a bill currently making its way through Congress as a win for the public, a former regional Environmental Protection Agency administrator is prepared to see devastating cuts to the office that could negatively impact human health. 'It's proposing severe cuts to both the scientific work that EPA's Office of Research and Development does and to the agency as a whole,' said Debra Shore, former administrator for EPA Region 5. 'It would severely reduce the agency's ability to fulfill its mission of protecting public health and the environment.' As the 'One Big Beautiful Bill' Act has passed the U.S. House of Representatives and moved to the Senate, activists nationwide have worried about the consequences. Shore said it's heartbreaking to see public servants at the EPA go through these cuts, especially as the administration tries to make the 'One Big Beautiful Bill' seem like a win. 'I have never worked with a group of such smart, devoted professionals who had a shared sense of mission as EPA employees,' Shore said. 'I know that's the case across the agency. … They could be working for far higher salaries in many cases, but they are dedicated to the foundational mission of the EPA, which is to protect public health and the environment.' On Tuesday and Wednesday, the EPA posted on Facebook, saying it 'delivers for all Americans.' 'One Big Beautiful Bill is putting American workers, taxpayers and families first,' the EPA's Tuesday post said. 'Under (Trump), the U.S. can unleash American energy while ensuring we have the cleanest air, land and water on (Earth).' The bill eliminates hundreds of billions of dollars in Green New Deal tax credits, repeals former President Joe Biden administration's electric vehicle mandates, and opens federal lands and waters to oil, gas, coal, geothermal and mineral leasing, according to the EPA's Tuesday post. According to the Wednesday post, the bill also 'streamlines onerous permitting processes,' refills the Strategic Petroleum reserve and 'delivers certainty to energy producers, saves and creates energy jobs, lowers energy costs for families.' A spokesperson for Sen. Todd Young, R-Indiana, provided a statement about the bill Friday. 'Senator Young continues to have conversations with his colleagues and stakeholders about improving the House-passed bill and addressing our nation's debt and deficit challenges,' said Leah Selk, spokesperson for Young. Representatives for Sen. Jim Banks, R-Indiana, did not respond to a request for comment Friday. Within the bill, the White House would also have the ability to cut federal agencies and reduce workforce, Shore said. 'This is just an utter abrogation of Congress' authority and power,' Shore said. 'It requires an annual report of planned reorganizational moves, and it also streamlines the ability of any future president to rebuild federal agencies because of some of the language in it.' Susan Thomas, director of policy and press for Just Transition Northwest Indiana, said it's concerning that EPA is treating the 'One Big Beautiful Bill' like a win, especially on social media platforms that are easily accessible. 'No one can take any information for granted anymore,' Thomas said. 'You must do your own research with trusted sources because the amount of greenwashing that's coming down is so dangerous. … This is becoming increasingly difficult, but it's more important than ever.' Thomas and Gary Advocates for Responsible Development board member Carolyn McCrady are both worried about the effects that environmental justice communities will face if the bill passes the Senate. McCrady expects public health to worsen as a result of EPA rollbacks. An October report from Industrious Labs found that most residents in Gary are in the top 10% of U.S. residents most at-risk for developing asthma and at-risk of low life expectancy. In 2020, Indiana had a lung cancer rate of 72.5 per 100,000 people, with Lake County as one of the state's counties with the highest cancer mortality rates, according to the American Lung Association. A 2016 JAMA Network report also found Gary as one of the top five U.S. cities with the lowest life expectancy at one point. 'I think people are going to be sicker faster,' McCrady said. 'I don't think people will be able to be served in the medical community in the same way, because in Indiana, millions of people are going to lose their health insurance because of the Medicaid cuts.' Although McCrady believes the EPA cuts are devastating, she isn't surprised to see them included in 'One Big Beautiful Bill.' Cuts will continue to put communities like Gary at a greater disadvantage, McCrady said. Thomas also believes that Northwest Indiana's environmental justice communities will struggle as a result of the 'One Big Beautiful Bill.' 'They've already stripped away all of the environmental justice provisions that had taken years to recognize and acknowledge and to start to put in place,' Thomas said. 'This is just a very sad state that we're in.'